Jiwei Chen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Jiwei Chen has a total of 13 co-authors. Here are the top co-authors by number of shared publications:
- Bin Zhu
Department of Nuclear Medicine Shanghai Cancer Center Fudan University Shanghai China
1 shared publication Boyong Wang
Department of General Surgery, Zhongnan Hospital of Wuhan University, Wuhan, Hubei 430071, P.R. China
1 shared publicationDongliang Wang
Department of Nuclear Medicine Shanghai Cancer Center Fudan University Shanghai China
1 shared publication- Feng Ding
Guangxi University
1 shared publication - Ling Liu
Department of Neurology, Stanford University, Stanford, USA
1 shared publication - Liu
Department of General Surgery, Zhongnan Hospital of Wuhan University, Wuhan, Hubei 430071, P.R. China
1 shared publication
Latest Publications
- Open Access
- 16 September 2026
- Published by Wiley in Advanced Science
- p. e77837
Granzyme B PET Imaging Reveals Lgmn + Macrophage‐Mediated Immune Evasion and Guides Immunotherapy in EGFR‐TKI‐Resistant NSCLC
Determining optimal therapies for EGFR‐mutant NSCLC after tyrosine kinase inhibitor (TKI) resistance remains challenging. Immune checkpoint inhibitors (ICIs) show limited efficacy, but some patients regain immunotherapy sensitivity post‐TKI. Non‐invasive monitoring to identify responders and understand persistent immune tolerance is needed. In this study, we prospectively evaluated a novel granzyme B‐targeted PET radiotracer, 68 Ga‐GZB, in a clinical cohort of NSCLC patients. 68 Ga‐GZB PET/CT accurately visualized early immune responses and stratified patients likely to benefit from immunotherapy. In preclinical models of acquired EGFR‐TKI resistance, we tracked dynamic immune reactivity via 68 Ga‐GZB PET/CT. Single‐cell transcriptomics and functional validation identified Lgmn + macrophages as a highly immunosuppressive subset driving persistent immunotherapy tolerance. Mechanistically, Lgmn + macrophages secrete extracellular vesicles (EVs) that deliver Lgmn directly into CD8 + T cells. Internalized Lgmn recruits the E3 ubiquitin ligase Chip, initiating the ubiquitination and proteasomal degradation of the glycolytic enzyme Eno1. This cascade severely impairs CD8 + T cell glycolysis, ultimately leading to CD8 + T cell exhaustion. Furthermore, we demonstrate that targeting of Lgmn synergizes with PD‐1 blockade to reactivate anti‐tumor immunity in TKI‐resistant models. Thus, 68 Ga‐GZB PET/CT provides a non‐invasive platform to stratify immunotherapy responses, and targeting Lgmn represents a novel combination strategy for EGFR‐TKI‐resistant NSCLC.
- 16 September 2026
- Published by Wiley in Advanced Science
- p. e77837
Open AccessGranzyme B PET Imaging Reveals Lgmn + Macrophage‐Mediated Immune Evasion and Guides Immunotherapy in EGFR‐TKI‐Resistant NSCLC
Determining optimal therapies for EGFR‐mutant NSCLC after tyrosine kinase inhibitor (TKI) resistance remains challenging. Immune checkpoint inhibitors (ICIs) show limited efficacy, but some patients regain immunotherapy sensitivity post‐TKI. Non‐invasive monitoring to identify responders and understand persistent immune tolerance is needed. In this study, we prospectively evaluated a novel granzyme B‐targeted PET radiotracer, 68 Ga‐GZB, in a clinical cohort of NSCLC patients. 68 Ga‐GZB PET/CT accurately visualized early immune responses and stratified patients likely to benefit from immunotherapy. In preclinical models of acquired EGFR‐TKI resistance, we tracked dynamic immune reactivity via 68 Ga‐GZB PET/CT. Single‐cell transcriptomics and functional validation identified Lgmn + macrophages as a highly immunosuppressive subset driving persistent immunotherapy tolerance. Mechanistically, Lgmn + macrophages secrete extracellular vesicles (EVs) that deliver Lgmn directly into CD8 + T cells. Internalized Lgmn recruits the E3 ubiquitin ligase Chip, initiating the ubiquitination and proteasomal degradation of the glycolytic enzyme Eno1. This cascade severely impairs CD8 + T cell glycolysis, ultimately leading to CD8 + T cell exhaustion. Furthermore, we demonstrate that targeting of Lgmn synergizes with PD‐1 blockade to reactivate anti‐tumor immunity in TKI‐resistant models. Thus, 68 Ga‐GZB PET/CT provides a non‐invasive platform to stratify immunotherapy responses, and targeting Lgmn represents a novel combination strategy for EGFR‐TKI‐resistant NSCLC.
- Open Access
- 3 February 2014
- Published by Spandidos Publications in Oncology Letters
- Vol. 7 (4) , 963-969
hSulf-1 inhibits cell proliferation and migration and promotes apoptosis by suppressing stat3 signaling in hepatocellular carcinoma
Human sulfatase‑1 (hSulf‑1) has been shown to desulfate cellular heparin sulfate proteoglycans and modulate several growth factors and cytokines. However, hSulf‑1 has not been previously shown to mediate the signal transducer and activator of transcription 3 (stat3) signaling pathway, which is known to regulate cell proliferation, motility and apoptosis. The present study investigated the role of hSulf‑1 in stat3 signaling in hepatocellular cancer. hSulf‑1 expression vector and stat3 small interfering RNA (siRNA) were constructed to control the expression of hSulf‑1 and stat3 in HepG2 cells. hSulf‑1 was found to inhibit the phosphorylation of stat3 and downregulate its targeted protein. MTT and Transwell chamber assays, as well as Annexin V/propidium iodide double‑staining methods, were used to examine the effects of hSulf‑1 on stat3‑mediated motility, proliferation and apoptosis in HepG2 cells. Transfection with hSulf‑1 cDNA and/or stat3 siRNA inhibited cell proliferation and motility, concurrent with G0/G1 and G2/M phase cell cycle arrest and apoptosis. Overall, the results of the current study suggested that hSulf‑1 functions as a negative regulator of proliferation and migration and as a positive regulator of apoptosis in hepatocellular carcinoma, at least partly via the downregulation of stat3 signaling.
- 3 February 2014
- Published by Spandidos Publications in Oncology Letters
- Vol. 7 (4) , 963-969
Open AccesshSulf-1 inhibits cell proliferation and migration and promotes apoptosis by suppressing stat3 signaling in hepatocellular carcinoma
Human sulfatase‑1 (hSulf‑1) has been shown to desulfate cellular heparin sulfate proteoglycans and modulate several growth factors and cytokines. However, hSulf‑1 has not been previously shown to mediate the signal transducer and activator of transcription 3 (stat3) signaling pathway, which is known to regulate cell proliferation, motility and apoptosis. The present study investigated the role of hSulf‑1 in stat3 signaling in hepatocellular cancer. hSulf‑1 expression vector and stat3 small interfering RNA (siRNA) were constructed to control the expression of hSulf‑1 and stat3 in HepG2 cells. hSulf‑1 was found to inhibit the phosphorylation of stat3 and downregulate its targeted protein. MTT and Transwell chamber assays, as well as Annexin V/propidium iodide double‑staining methods, were used to examine the effects of hSulf‑1 on stat3‑mediated motility, proliferation and apoptosis in HepG2 cells. Transfection with hSulf‑1 cDNA and/or stat3 siRNA inhibited cell proliferation and motility, concurrent with G0/G1 and G2/M phase cell cycle arrest and apoptosis. Overall, the results of the current study suggested that hSulf‑1 functions as a negative regulator of proliferation and migration and as a positive regulator of apoptosis in hepatocellular carcinoma, at least partly via the downregulation of stat3 signaling.